Intraperitoneal carboplatin

Favorable results in women with minimal residual ovarian cancer after cisplatin therapy

J. L. Speyer, U. Beller, N. Colombo, J. Sorich, J. C. Wernz, H. Hochster, M. Green, R. Porges, F. M. Muggia, R. Canetta, E. M. Beckman

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

From August 1985 to November 1989 we conducted a trial of intraperitoneal (IP) carboplatin including a dose-escalation design in 25 women with advanced gynecologic malignancies. All had extensive prior therapy with cisplatin (median cumulative dose, 525 mg/m 2). Carboplatin was administered IP in 2 L of 1.5% dextrose with a 4-hour dwell time every 4 weeks for six cyles at a starting dose of 200 mg/m 2. Patients with reduced creatinine clearance (30 to 60 cc/min) were escalated more slowly than those with high (> 66 cc/min) clearance. Thrombocytopenia was dose-limiting and often more severe in patients with compromised renal function; there was no local drug toxicity. The median time of follow-up is 25 months. Complete responses (CRs) were documented in six of 23 assessable patients (26%) by repeat laparotomy, and an additional 11 patients (48%) had no disease evident by noninvasive restaging. Five of the CRs and six of the patients with no clinically evident disease have relapsed from 3 to 40 months after therapy. Six patients (26%) are alive and free of disease 8 to 47 (median, 20) months after therapy. IP carboplatin is effective against relapsed ovarian cancer, even after prior cisplatin therapy.

Original languageEnglish
Pages (from-to)1335-1341
Number of pages7
JournalJournal of Clinical Oncology
Volume8
Issue number8
Publication statusPublished - 1990

Fingerprint

Carboplatin
Residual Neoplasm
Ovarian Neoplasms
Cisplatin
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Thrombocytopenia
Laparotomy
Creatinine
Kidney
Glucose
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Speyer, J. L., Beller, U., Colombo, N., Sorich, J., Wernz, J. C., Hochster, H., ... Beckman, E. M. (1990). Intraperitoneal carboplatin: Favorable results in women with minimal residual ovarian cancer after cisplatin therapy. Journal of Clinical Oncology, 8(8), 1335-1341.

Intraperitoneal carboplatin : Favorable results in women with minimal residual ovarian cancer after cisplatin therapy. / Speyer, J. L.; Beller, U.; Colombo, N.; Sorich, J.; Wernz, J. C.; Hochster, H.; Green, M.; Porges, R.; Muggia, F. M.; Canetta, R.; Beckman, E. M.

In: Journal of Clinical Oncology, Vol. 8, No. 8, 1990, p. 1335-1341.

Research output: Contribution to journalArticle

Speyer, JL, Beller, U, Colombo, N, Sorich, J, Wernz, JC, Hochster, H, Green, M, Porges, R, Muggia, FM, Canetta, R & Beckman, EM 1990, 'Intraperitoneal carboplatin: Favorable results in women with minimal residual ovarian cancer after cisplatin therapy', Journal of Clinical Oncology, vol. 8, no. 8, pp. 1335-1341.
Speyer, J. L. ; Beller, U. ; Colombo, N. ; Sorich, J. ; Wernz, J. C. ; Hochster, H. ; Green, M. ; Porges, R. ; Muggia, F. M. ; Canetta, R. ; Beckman, E. M. / Intraperitoneal carboplatin : Favorable results in women with minimal residual ovarian cancer after cisplatin therapy. In: Journal of Clinical Oncology. 1990 ; Vol. 8, No. 8. pp. 1335-1341.
@article{30fb48b0e67e4cf9828eab4a18d33e33,
title = "Intraperitoneal carboplatin: Favorable results in women with minimal residual ovarian cancer after cisplatin therapy",
abstract = "From August 1985 to November 1989 we conducted a trial of intraperitoneal (IP) carboplatin including a dose-escalation design in 25 women with advanced gynecologic malignancies. All had extensive prior therapy with cisplatin (median cumulative dose, 525 mg/m 2). Carboplatin was administered IP in 2 L of 1.5{\%} dextrose with a 4-hour dwell time every 4 weeks for six cyles at a starting dose of 200 mg/m 2. Patients with reduced creatinine clearance (30 to 60 cc/min) were escalated more slowly than those with high (> 66 cc/min) clearance. Thrombocytopenia was dose-limiting and often more severe in patients with compromised renal function; there was no local drug toxicity. The median time of follow-up is 25 months. Complete responses (CRs) were documented in six of 23 assessable patients (26{\%}) by repeat laparotomy, and an additional 11 patients (48{\%}) had no disease evident by noninvasive restaging. Five of the CRs and six of the patients with no clinically evident disease have relapsed from 3 to 40 months after therapy. Six patients (26{\%}) are alive and free of disease 8 to 47 (median, 20) months after therapy. IP carboplatin is effective against relapsed ovarian cancer, even after prior cisplatin therapy.",
author = "Speyer, {J. L.} and U. Beller and N. Colombo and J. Sorich and Wernz, {J. C.} and H. Hochster and M. Green and R. Porges and Muggia, {F. M.} and R. Canetta and Beckman, {E. M.}",
year = "1990",
language = "English",
volume = "8",
pages = "1335--1341",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Intraperitoneal carboplatin

T2 - Favorable results in women with minimal residual ovarian cancer after cisplatin therapy

AU - Speyer, J. L.

AU - Beller, U.

AU - Colombo, N.

AU - Sorich, J.

AU - Wernz, J. C.

AU - Hochster, H.

AU - Green, M.

AU - Porges, R.

AU - Muggia, F. M.

AU - Canetta, R.

AU - Beckman, E. M.

PY - 1990

Y1 - 1990

N2 - From August 1985 to November 1989 we conducted a trial of intraperitoneal (IP) carboplatin including a dose-escalation design in 25 women with advanced gynecologic malignancies. All had extensive prior therapy with cisplatin (median cumulative dose, 525 mg/m 2). Carboplatin was administered IP in 2 L of 1.5% dextrose with a 4-hour dwell time every 4 weeks for six cyles at a starting dose of 200 mg/m 2. Patients with reduced creatinine clearance (30 to 60 cc/min) were escalated more slowly than those with high (> 66 cc/min) clearance. Thrombocytopenia was dose-limiting and often more severe in patients with compromised renal function; there was no local drug toxicity. The median time of follow-up is 25 months. Complete responses (CRs) were documented in six of 23 assessable patients (26%) by repeat laparotomy, and an additional 11 patients (48%) had no disease evident by noninvasive restaging. Five of the CRs and six of the patients with no clinically evident disease have relapsed from 3 to 40 months after therapy. Six patients (26%) are alive and free of disease 8 to 47 (median, 20) months after therapy. IP carboplatin is effective against relapsed ovarian cancer, even after prior cisplatin therapy.

AB - From August 1985 to November 1989 we conducted a trial of intraperitoneal (IP) carboplatin including a dose-escalation design in 25 women with advanced gynecologic malignancies. All had extensive prior therapy with cisplatin (median cumulative dose, 525 mg/m 2). Carboplatin was administered IP in 2 L of 1.5% dextrose with a 4-hour dwell time every 4 weeks for six cyles at a starting dose of 200 mg/m 2. Patients with reduced creatinine clearance (30 to 60 cc/min) were escalated more slowly than those with high (> 66 cc/min) clearance. Thrombocytopenia was dose-limiting and often more severe in patients with compromised renal function; there was no local drug toxicity. The median time of follow-up is 25 months. Complete responses (CRs) were documented in six of 23 assessable patients (26%) by repeat laparotomy, and an additional 11 patients (48%) had no disease evident by noninvasive restaging. Five of the CRs and six of the patients with no clinically evident disease have relapsed from 3 to 40 months after therapy. Six patients (26%) are alive and free of disease 8 to 47 (median, 20) months after therapy. IP carboplatin is effective against relapsed ovarian cancer, even after prior cisplatin therapy.

UR - http://www.scopus.com/inward/record.url?scp=0024989883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024989883&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 1335

EP - 1341

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -